Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring (2022)
- Authors:
- USP affiliated authors: SILVA, CLOVIS ARTUR ALMEIDA DA - FM ; BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM ; KUPA, LEONARD DE VINCI KANDA - FM
- Unidade: FM
- DOI: 10.4155/bio-2022-0077
- Subjects: LÚPUS ERITEMATOSO CUTÂNEO; FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Bioanalysis
- ISSN: 1757-6180
- Volume/Número/Paginação/Ano: v. 14, n. 15, p. 1039-1050, 2022
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
NOVELLINO, Renata Soares et al. Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring. Bioanalysis, v. 14, n. 15, p. 1039-1050, 2022Tradução . . Disponível em: https://doi.org/10.4155/bio-2022-0077. Acesso em: 09 fev. 2026. -
APA
Novellino, R. S., Chalom, M. Y., Romano, P., Ebner, P. de A. R., Seraphim, J. C., Amaral, A. C. S. do, et al. (2022). Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring. Bioanalysis, 14( 15), 1039-1050. doi:10.4155/bio-2022-0077 -
NLM
Novellino RS, Chalom MY, Romano P, Ebner P de AR, Seraphim JC, Amaral ACS do, Duarte NJC, Silva CAA da, Bonfa ESD de O, Kupa L de VK. Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring [Internet]. Bioanalysis. 2022 ; 14( 15): 1039-1050.[citado 2026 fev. 09 ] Available from: https://doi.org/10.4155/bio-2022-0077 -
Vancouver
Novellino RS, Chalom MY, Romano P, Ebner P de AR, Seraphim JC, Amaral ACS do, Duarte NJC, Silva CAA da, Bonfa ESD de O, Kupa L de VK. Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring [Internet]. Bioanalysis. 2022 ; 14( 15): 1039-1050.[citado 2026 fev. 09 ] Available from: https://doi.org/10.4155/bio-2022-0077 - SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy
- Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome
- Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
- Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
- Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
- Lupus nephritis-related issues during COVID-19 pandemic quarantine
- Initial Benchmarking of the Quality of Medical Care in Childhood-Onset Systemic Lupus Erythematosus
- High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting
- Latent tuberculosis infection screening in juvenile idiopathic arthritis patients preceding anti-TNF therapy in a tuberculosis high-risk country
- 23-valent polysaccharice pneumococcal vaccine in juvenile idiopathic arthritis patients: anti-tumor necrosis factor therapy role in short and long-term immunogenicity
Informações sobre o DOI: 10.4155/bio-2022-0077 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
